Dupilumab Improves Lung Function in CRSwNP and Comorbid Asthma and COPD Features
Treatment with dupilumab led to significant improvements in lung function by 16 weeks and up to 24 weeks in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma plus clinical features of COPD.